News articles about Codexis (NASDAQ:CDXS) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.0567281830265 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

CDXS has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and set a $8.50 price objective on shares of Codexis in a research note on Tuesday, November 21st. Jefferies Group reiterated a “buy” rating and set a $9.00 price objective (up previously from $8.00) on shares of Codexis in a research note on Monday, October 2nd. ValuEngine upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Codexis has an average rating of “Hold” and a consensus price target of $7.50.

Codexis (NASDAQ CDXS) opened at $7.65 on Thursday. Codexis has a 12 month low of $3.60 and a 12 month high of $7.95.

TRADEMARK VIOLATION WARNING: “Codexis (CDXS) Earns Daily Media Impact Score of 0.24” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/codexis-cdxs-earns-daily-media-impact-score-of-0-24/1762884.html.

About Codexis

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with Analyst Ratings Network's FREE daily email newsletter.